(NASDAQ: SPRY) Ars Pharmaceuticals's forecast annual revenue growth rate of 36.88% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.42%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.03%.
Ars Pharmaceuticals's revenue in 2026 is $116,927,000.On average, 6 Wall Street analysts forecast SPRY's revenue for 2026 to be $13,169,811,633, with the lowest SPRY revenue forecast at $11,792,465,933, and the highest SPRY revenue forecast at $14,608,814,687. On average, 6 Wall Street analysts forecast SPRY's revenue for 2027 to be $19,347,480,581, with the lowest SPRY revenue forecast at $15,398,426,590, and the highest SPRY revenue forecast at $22,576,535,808.
In 2028, SPRY is forecast to generate $30,680,499,789 in revenue, with the lowest revenue forecast at $23,000,181,489 and the highest revenue forecast at $35,388,337,007.